Literature DB >> 12384566

Genome-wide allelotyping of a new in vitro model system reveals early events in breast cancer progression.

Zheng Li1, Zhen Hang Meng, Aejaz Sayeed, Refaat Shalaby, Britt-Marie Ljung, Shanaz H Dairkee.   

Abstract

Toward the goal of identifying early genetic losses, which mediate the release of human breast epithelium from replicative suppression leading to cellular immortalization, we have used a newly developed in vitro model system. This system consists of epithelial cultures derived from noncancerous breast tissue, treated with the chemical carcinogen N-ethyl-N-nitrosourea, and continuously passaged to yield cell populations culminating in the immortal phenotype. Genome-wide allelotyping of early passage N-ethyl-N-nitrosourea-exposed cell populations revealed aberrations at >10% (18 of 169) loci examined. Allelic losses encompassing chromosomes 6q24-6q27, implicating immortalization-associated candidate genes, hZAC and SEN6, occurred in two independently derived cell lines before the Hayflick limit. Additional LOH sites were present in one cell line at 3p11-3p26, 11p15, and 20p12-13. Allelic losses reported in this cell line preceded detectable levels of telomerase activity and the occurrence of p53-related aberrations. Information gained from the search for early immortalization-associated genetic deletions in cultured cells was applied in a novel approach toward the analysis of morphologically normal terminal ductal lobular units microdissected from 20 cases of ductal carcinoma in situ. Notably, clonal allelic losses at chromosome 3p24 and 6q24 were an early occurrence in adjoining terminal ductal lobular units of a proportion of primary tumors, which displayed loss of heterozygosity (3 of 11 and 3 of 6, respectively). The biological insights provided by the new model system reported here strongly suggest that early allelic losses delineated in immortalized cultures and validated in vivo could serve as surrogate endpoints to assist in the identification and intervention of high-risk benign breast tissue, which sustains the potential for continuous proliferation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384566

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

2.  Elevated expression of Tie1 is accompanied by acquisition of cancer stemness properties in colorectal cancer.

Authors:  Miku Torigata; Daishi Yamakawa; Nobuyuki Takakura
Journal:  Cancer Med       Date:  2017-05-02       Impact factor: 4.452

Review 3.  Experimental identification of cancer driver alterations in the era of pan-cancer genomics.

Authors:  Michael Korenjak; Jiri Zavadil
Journal:  Cancer Sci       Date:  2019-10-31       Impact factor: 6.716

Review 4.  Genetic alteration and gene expression modulation during cancer progression.

Authors:  Cathie Garnis; Timon P H Buys; Wan L Lam
Journal:  Mol Cancer       Date:  2004-03-22       Impact factor: 27.401

5.  A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue.

Authors:  Shanaz H Dairkee; Youngran Ji; Yong Ben; Dan H Moore; Zhenhang Meng; Stefanie S Jeffrey
Journal:  BMC Genomics       Date:  2004-07-19       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.